These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22492589)

  • 1. Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study.
    Holthoff V; Ferris S; Gauthier S; Ihl R; Robert P; Winblad B; Sternberg K; Tennigkeit F;
    Int J Geriatr Psychiatry; 2013 Feb; 28(2):164-72. PubMed ID: 22492589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
    Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
    J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
    Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
    Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
    Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
    Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
    Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
    J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.
    Hellweg R; Wirth Y; Janetzky W; Hartmann S
    Int J Geriatr Psychiatry; 2012 Jun; 27(6):651-6. PubMed ID: 22513699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria].
    Schmidt R; Baumhackl U; Berek K; Brücke T; Kapeller P; Lechner A; Rainer M; Stögerer EM
    Neuropsychiatr; 2010; 24(2):125-31. PubMed ID: 20605008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine (Ebixa) in clinical practice - results of an observational study.
    Calabrese P; Essner U; Forstl H
    Dement Geriatr Cogn Disord; 2007; 24(2):111-7. PubMed ID: 17622714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
    Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine treatment in outpatients with mild Alzheimer's disease.
    Richarz U; Gaudig M; Rettig K; Schauble B
    Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
    Bullock R; Erkinjuntti T; Lilienfeld S;
    Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
    Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
    Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.